Investing into best-in-class therapeutics companies
Syncona has £55.0 million of value in its investments, typically where we do not hold Board seats or manage the investment actively alongside executive teams. Our assets held within our investments are CRT Pioneer Fund, Forcefield Therapeutics, Biomodal (formerly Cambridge Epigenetix), and Adaptimmune.
Key facts
Unless stated all financials at 31 December 2023
£58m
Value in its investments
4.6%
Of NAV
£8.8m
Our largest investment in 2023
Assets held within our investments
